Lateral Epicondylitis (Tennis Elbow) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lateral Epicondylitis (Tennis Elbow) Market Outlook

Thelansis’s “Lateral Epicondylitis (Tennis Elbow) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lateral Epicondylitis (Tennis Elbow) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lateral Epicondylitis (Tennis Elbow) Overview

Lateral epicondylitis, also known as Tennis elbow, is an injury caused by an eccentric overload of the common extensor tendon at the extensor carpi radialis brevis (ECRB) tendon's origin. The main cause of tennis elbow is repetitive strain brought on by holding something repeatedly and extending the wrist. People who play badminton, squash, tennis, or any other activity requiring repetitive wrist extension, radial deviation, and forearm supination are prone to it. Tennis elbow is frequently an overuse injury caused mostly by repetitive strain from holding objects repeatedly or extending the wrist. The main cause of this illness is a degenerative process brought on by overuse of the common extensor tendon and the extensor carpi radialis brevis. Imaging is frequently not required for the clinical diagnosis of lateral epicondylitis. If the history and physical examination point to other injuries or conditions, the provider may consider ordering an elbow radiography series (anteroposterior and lateral). Depending on the severity of the discomfort, rest from the aggravating activity is the first line of treatment for lateral epicondylitis. NSAIDs either topically or orally and ice applied after exercise can help manage pain. It has also been demonstrated that occupational or physical therapy concentrating on forearm strengthening and stretching, followed by a progression to eccentric muscle strengthening of the common extensor tendon, is beneficial.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: